Literature DB >> 26668090

Performance of informative priors skeptical of large treatment effects in clinical trials: A simulation study.

Claudia Pedroza1, Weilu Han1, Van Thi Thanh Truong1, Charles Green1, Jon E Tyson1.   

Abstract

One of the main advantages of Bayesian analyses of clinical trials is their ability to formally incorporate skepticism about large treatment effects through the use of informative priors. We conducted a simulation study to assess the performance of informative normal, Student- t, and beta distributions in estimating relative risk (RR) or odds ratio (OR) for binary outcomes. Simulation scenarios varied the prior standard deviation (SD; level of skepticism of large treatment effects), outcome rate in the control group, true treatment effect, and sample size. We compared the priors with regards to bias, mean squared error (MSE), and coverage of 95% credible intervals. Simulation results show that the prior SD influenced the posterior to a greater degree than the particular distributional form of the prior. For RR, priors with a 95% interval of 0.50-2.0 performed well in terms of bias, MSE, and coverage under most scenarios. For OR, priors with a wider 95% interval of 0.23-4.35 had good performance. We recommend the use of informative priors that exclude implausibly large treatment effects in analyses of clinical trials, particularly for major outcomes such as mortality.

Keywords:  Bayesian analysis; binary data; clinical trial; informative priors; large treatment effects; robust priors

Mesh:

Year:  2015        PMID: 26668090     DOI: 10.1177/0962280215620828

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  6 in total

1.  Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke).

Authors:  Andrew D Barreto; Gary A Ford; Loren Shen; Claudia Pedroza; Jon Tyson; Chunyan Cai; Mohammad H Rahbar; James C Grotta
Journal:  Stroke       Date:  2017-05-15       Impact factor: 7.914

2.  Methodological issues in the design and analyses of neonatal research studies: Experience of the NICHD Neonatal Research Network.

Authors:  Abhik Das; Jon Tyson; Claudia Pedroza; Barbara Schmidt; Marie Gantz; Dennis Wallace; William E Truog; Rosemary D Higgins
Journal:  Semin Perinatol       Date:  2016-06-22       Impact factor: 3.300

3.  Effect of Therapeutic Hypothermia Initiated After 6 Hours of Age on Death or Disability Among Newborns With Hypoxic-Ischemic Encephalopathy: A Randomized Clinical Trial.

Authors:  Abbot R Laptook; Seetha Shankaran; Jon E Tyson; Breda Munoz; Edward F Bell; Ronald N Goldberg; Nehal A Parikh; Namasivayam Ambalavanan; Claudia Pedroza; Athina Pappas; Abhik Das; Aasma S Chaudhary; Richard A Ehrenkranz; Angelita M Hensman; Krisa P Van Meurs; Lina F Chalak; Amir M Khan; Shannon E G Hamrick; Gregory M Sokol; Michele C Walsh; Brenda B Poindexter; Roger G Faix; Kristi L Watterberg; Ivan D Frantz; Ronnie Guillet; Uday Devaskar; William E Truog; Valerie Y Chock; Myra H Wyckoff; Elisabeth C McGowan; David P Carlton; Heidi M Harmon; Jane E Brumbaugh; C Michael Cotten; Pablo J Sánchez; Anna Maria Hibbs; Rosemary D Higgins
Journal:  JAMA       Date:  2017-10-24       Impact factor: 56.272

4.  Estimating relative risks in multicenter studies with a small number of centers - which methods to use? A simulation study.

Authors:  Claudia Pedroza; Van Thi Thanh Truong
Journal:  Trials       Date:  2017-11-02       Impact factor: 2.279

5.  Handling Poor Accrual in Pediatric Trials: A Simulation Study Using a Bayesian Approach.

Authors:  Danila Azzolina; Giulia Lorenzoni; Silvia Bressan; Liviana Da Dalt; Ileana Baldi; Dario Gregori
Journal:  Int J Environ Res Public Health       Date:  2021-02-21       Impact factor: 3.390

6.  Advantages of Bayesian monitoring methods in deciding whether and when to stop a clinical trial: an example of a neonatal cooling trial.

Authors:  Claudia Pedroza; Jon E Tyson; Abhik Das; Abbot Laptook; Edward F Bell; Seetha Shankaran
Journal:  Trials       Date:  2016-07-22       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.